Allergen (AGN) Trading Below Standalone Value Following New Treasury Action - RBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- SpaceX slides, tech stocks dip — what’s moving markets
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Pfizer and Allergan Issue Statement
April 4, 2016 7:05 PM EDTNEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and Allergan plc (NYSE: AGN) today issued the following statement regarding the recently issued Department of Treasury Notice:
We are conducting a review of the U.S. Department of Treasurys actions announced today. Prior to completing the review, we wont speculate on any potential impact.
NO OFFER OR SOLICITATION
This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an... More
